UBX-382 is an orally bioavailable proteolysis-targeting chimera (PROTAC) that targets Bruton's tyrosine kinase (BTK), inactivating B-cell receptor signaling; it exhibits potent degradation activity against both wild-type and mutant BTK proteins and demonstrates antitumor activity in a mouse TMD-8 cell xenograft model.